Andrew Bruyn
Foot & Ankle Surgery · Buda, TXNPI 1538574173
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Arthrex at 32.8% of the total. Reporting peaked in 2022 at $2,053 and has fallen 73.1% since, to $553 in 2025.
Across 54 payments — averaging $117.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$2K
- Paragon 28, Inc.$1K
- Core Surgical Group$912
- Stryker$778
- Medinc Of Texas$444
- Treace Medical Concepts, Inc.$210
- plus $615 from 7 others
What the payments were for
- Travel & lodging$2,43738%
- Food & beverage$2,67442%
- Education$1,25920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 21 | $2,092 |
| Paragon 28, Inc. | 4 | $1,319 |
| Core Surgical Group | 6 | $912 |
| Stryker(2 entities) | 8 | $778 |
| Medinc Of Texas | 3 | $444 |
| Treace Medical Concepts, Inc. | 2 | $210 |
| Medtronic | 1 | $174 |
| Nevro Corp. | 3 | $172 |
| Bioventus LLC | 2 | $161 |
| Argenx US, Inc. | 1 | $37 |
| Misonix Inc | 1 | $32 |
| Integra Lifesciences Corporation | 1 | $20 |
| Zimmer Biomet | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CITREFIX$291
- INTELLIS ADAPTIVESTIM$174
- PROSTEP MICA$168
- Lapiplasty System$151
- Exogen Ultrasound Bone Healing System$141
- EASYFUSE$134
- ORTHOLOC 2 LAPIFUSE$134
- 7 X 23MM CITRELOCK IMPLANT$134
- AUGMENT$128
- Senza$116
How this compares
$6,370 in reported general payments places this provider in the 60th percentile of 684 foot & ankle surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gentamicin Sulfate | 137 | $2,790 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 47 | $850 |
| Cephalexin | 49 | $237 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $206 |
| Gabapentin | 41 | $169 |
| Terbinafine Hcl | 15 | $148 |
| Ondansetron Hcl | 29 | $138 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $124 |
| Clindamycin Hcl | 11 | $103 |
| Meloxicam | 38 | $60 |
| Pregabalin | 14 | $34 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Buda
- William McGarveyKaty$3.5M
- Eugene CurryDallas$3.1M
- Graham HamiltonEdinburg$2.1M
- Mark DaltonAustin$1.9M
- Kevin VarnerHouston$1.1M
- Paul KimDallas$928K
- Sherman NaglerHouston$602K
- John EarlyDallas$553K
- Michael DowneySouthlake$475K
- Abdul NurudeenHouston$404K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.